0001192482-19-000222.txt : 20190429 0001192482-19-000222.hdr.sgml : 20190429 20190429185543 ACCESSION NUMBER: 0001192482-19-000222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190425 FILED AS OF DATE: 20190429 DATE AS OF CHANGE: 20190429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fallon John A. CENTRAL INDEX KEY: 0001560152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 19777755 MAIL ADDRESS: STREET 1: C/O INSULET CORPORATION STREET 2: 9 OAK PARK DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-04-25 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001560152 Fallon John A. C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 1 0 0 0 Common Stock 2019-04-25 4 A 0 4707 0 A 9335 D Stock Option (Right to Purchase) 14.57 2019-04-25 4 A 0 9414 0 A 2029-04-25 Common Stock 9414 9414 D Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. /s/ Paul Brannelly as Attorney-In-Fact For John A. Fallon, M.D. 2019-04-29